A 28-year-old woman is brought to the emergency department by her friends. She is naked except for a blanket and speaking rapidly and incoherently. Her friends say that she was found watering her garden naked and refused to put on any clothes when they tried to make her do so, saying that she has accepted how beautiful she is inside and out. Her friends say she has also purchased a new car she can not afford. They are concerned about her, as they have never seen her behave this way before. For the past week, she has not shown up at work and has been acting ‘strangely’. They say she was extremely excited and has been calling them at odd hours of the night to tell them about her future plans. Which of the following drug mechanisms will help with the long-term management this patient’s symptoms?
A 29-year-old woman presents to her primary physician with complaints of episodic late-night agitations and insomnia to an extent that her work is at stake due to her poor performance for months. Her husband reports that she has recently spent their savings on a shopping spree. He is worried that she might be taking illicit substances as her behavior changes very often. The toxicology screen comes back negative. The physician diagnoses her with bipolar disorder and prescribes her a medication. Which of the following statements best describes the prescribed therapy?
A 25-year-old woman presents to the emergency department when she was found trying to direct traffic on the highway in the middle of the night. The patient states that she has created a pooled queuing system that will drastically reduce the traffic during rush hour. When speaking with the patient, she does not answer questions directly and is highly distractible. She is speaking very rapidly in an effort to explain her ideas to you. The patient has a past medical history of depression for which she was started on a selective serotonin reuptake inhibitor (SSRI) last week. Physical exam is deferred as the patient is highly irritable. The patient’s home medications are discontinued and she is started on a mortality-lowering agent. The next morning, the patient is resting peacefully. Which of the following is the next best step in management?
A 20-year-old man presents to the emergency department by his father for not sleeping for 2 nights consecutively. His father noticed that the patient has been in an unusual mood. One day ago, the patient disrobed in front of guests after showering. He has also had lengthy conversations with strangers. One month ago, the patient took out a large loan from a bank in order to fund a business idea he has not yet started. He also borrowed his father's credit card to make a spontaneous trip to Switzerland by himself for a few days, where he spent over 30,000 dollars. His father notes that there have been episodes where he would not leave his bed and remained in his room with the lights off. During these episodes, he sleeps for approximately 15 hours. On physical exam, he is talkative, distractable, and demonstrates a flight of ideas. His speech is pressured, difficult to interrupt, and he asks intrusive questions. Which of the following is the best treatment option for this patient?
A 26-year-old woman is found wandering in the street at 3 AM in the morning shouting about a new cure for cancer. When interviewed in the psychiatric triage unit, she speaks rapidly without pauses and continues to boast of her upcoming contribution to science. When the physician attempts to interrupt her, she becomes angry and begins to shout about all of her "accomplishments" in the last week. She states that because she anticipates a substantial sum of money from the Nobel Prize she will win, she bought a new car and diamond earrings. In addition, the patient divulges that she is 8 weeks pregnant with a fetus who is going to "change the course of history." Her chart in the electronic medical record shows an admission 3 months ago for suicidality and depression. She was released on fluoxetine after being stabilized, but the patient now denies ever taking any medications that "could poison my brain." Urine pregnancy test is positive. Which of the following is a potential adverse outcome of lithium, the drug shown to reduce suicide-related mortality in bipolar patients?
A 16-year-old girl presents with multiple manic and hypomanic episodes. The patient says that these episodes started last year and have progressively worsened. She is anxious to start treatment, so this will not impact her school or social life. The patient was prescribed an anticonvulsant drug that is also used to treat her condition. Which of the following is the drug most likely prescribed to this patient?
A 27-year-old woman presents to the psychiatrist due to feelings of sadness for the past 3 weeks. She was let go from her job 1 month ago, and she feels as though her whole life is coming to an end. She is unable to sleep well at night and also finds herself crying at times during the day. She has not been able to eat well and has been losing weight as a result. She has no will to go out and meet with her friends, who have been extremely supportive during this time. Her doctor gives her an antidepressant which blocks the reuptake of both serotonin and norepinephrine to help with these symptoms. One week later, she is brought to the emergency room by her friends who say that she was found to be in a state of euphoria. They mention bizarre behavior, one of which is booking a plane ticket to New York, even though she has 3 interviews lined up the same week. Her words cannot be understood as she is speaking very fast, and she is unable to sit in one place for the examination. Which of the following was most likely prescribed by her psychiatrist?
A 19-year-old female college student is brought into the emergency department by her boyfriend. The boyfriend reports that the patient got caught stealing from the company she works for and subsequently got fired. The boyfriend received a text that evening saying “I’ll miss you.” When he arrived at her dorm room, the patient was slumped in the shower covered in blood. The patient agreed to be driven to the emergency room. When asked about what happened, the patient replies “I just want out of this life.” The patient has bipolar disorder, and takes lithium as prescribed. She has a psychiatrist she sees every week, which the boyfriend confirms. She has never had a prior suicide attempt nor has she ever been hospitalized for a psychiatric disorder. The patient’s vitals are stable. Upon physical examination, a 4 centimeter vertical incision is noted on the patient’s left forearm. During the patient’s laceration repair, she asks if she will be admitted. She states, “these ups and downs are common for me, but I feel better now.” She verbalizes that she understands that she overreacted. She asks to go home, and her boyfriend insists that he will stay with her. They both confirm that neither of them have guns or know any peers with access to guns. Which of the following is the most appropriate management for the patient?
A 22-year-old woman is brought to the emergency department 20 minutes after being detained by campus police for attempting to steal from the bookstore. Her roommate says that the patient has been acting strangely over the last 2 weeks. She has not slept in 4 days and has painted her room twice in that time span. She has also spent all of her savings on online shopping and lottery tickets. She has no history of psychiatric illness or substance abuse, and takes no medications. During the examination, she is uncooperative, combative, and refusing care. She screams, “Let me go, God has a plan for me and I must go finish it!”. Her temperature is 37.2°C (99°F), pulse is 75/min, respirations are 16/min, and blood pressure is 130/80 mm Hg. Physical examination shows no abnormalities. On mental status examination, she describes her mood as “amazing.” She has a labile affect, speaks rapidly, and her thought process is tangential. She denies having any hallucinations. Which of the following is the most appropriate initial pharmacotherapy?
A 32-year-old woman is brought to the physician by her husband, who is concerned about her ability to care for herself. Three weeks ago, she quit her marketing job to start a clothing company. Since then, she has not slept more than 4 hours per night because she has been working on her business plans. She used a significant portion of their savings to fund business trips to Switzerland in order to buy “only the best quality fabrics in the world.” She has not showered and has eaten little during the past 3 days. She has had 2 similar episodes a few years back that required hospitalization and treatment in a psychiatry unit. She has also suffered from periods of depression. She is currently not taking any medications. She appears unkempt and agitated, pacing up and down the room. She speaks very fast without interruption about her business ideas. She has no suicidal ideation or ideas of self-harm. Toxicology screening is negative. Which of the following is the most appropriate pharmacotherapy for the management of this patient?
Explanation: ***Inhibition of inositol monophosphatase and inositol polyphosphate 1-phosphatase*** - The patient's symptoms (euphoria, grandiosity, reduced need for sleep, impulsivity, rapid speech, and unusual behavior) are classic for a **manic episode**, strongly suggesting **bipolar disorder**. - **Lithium** is a mood stabilizer used for long-term management of bipolar disorder, and its primary molecular action is thought to involve the **inhibition of inositol phosphatases**, thereby depleting inositol and modulating intracellular signaling. *Increase the concentration of dopamine and norepinephrine at the synaptic cleft* - This mechanism describes the action of **stimulants** or some **antidepressants** (like TCAs or SNRIs), which could exacerbate manic symptoms in bipolar disorder. - Increasing dopamine and norepinephrine would likely worsen the current patient's **hyperactivity**, **agitation**, and **psychosis**. *Inhibit the reuptake norepinephrine and serotonin from the presynaptic cleft* - This mechanism is characteristic of **antidepressants** (e.g., SSRIs, SNRIs) used to treat depression. - Administering such drugs during a manic episode can precipitate or worsen **mania** or induce **rapid cycling** in bipolar patients. *Modulate the activity of Ƴ-aminobutyric acid receptors* - This describes the action of **benzodiazepines** or some **antiepileptic drugs** (e.g., valproate, lamotrigine). - While some antiepileptic drugs (like valproate) are used as mood stabilizers, the direct modulation of GABA receptors to **increase GABAergic activity** (as with benzodiazepines) is typically for acute agitation and anxiety, not the primary long-term mood stabilization for bipolar disorder. *Acts as an antagonist at the dopamine, serotonin, and adrenergic receptors* - This mechanism generally describes the action of **antipsychotic medications** (e.g., olanzapine, quetiapine, risperidone). - While antipsychotics are effective for acute mania and some are used in long-term maintenance of bipolar disorder, the question asks for the primary drug mechanism for long-term management which is **Lithium's mechanism of action**, targeting intracellular signaling rather than broad receptor antagonism.
Explanation: ***The patient should be informed about the risk of thyroid function impairment*** - **Lithium**, a common mood stabilizer for bipolar disorder, can interfere with **thyroid hormone synthesis** and release, leading to **hypothyroidism**. - Regular monitoring of **thyroid function tests (TFTs)** is crucial for patients on lithium therapy. *She can be pregnant if she wishes to do so while on this medication* - **Lithium** is known to be **teratogenic** and is associated with an increased risk of **Ebstein's anomaly** in the fetus, especially when taken in the first trimester. - Therefore, it is generally **contraindicated or used with extreme caution** during pregnancy, and women of childbearing age should be counseled on effective contraception. *Patient can not be switched to any other therapy if this therapy fails* - Several other medications, such as **valproate**, **carbamazepine**, and **atypical antipsychotics**, are effective in treating bipolar disorder and can be used if initial therapy fails or is not tolerated. - Treatment for bipolar disorder is often **individualized**, and patients may require trials of different medications or combinations to find the most effective regimen. *The prescribed medication does not require therapeutic monitoring* - **Lithium** has a **narrow therapeutic index**, meaning the difference between an effective dose and a toxic dose is small. - Regular **serum lithium levels** must be monitored to ensure the drug remains within the therapeutic range (0.6-1.2 mEq/L) and to prevent toxicity. *The medication can be discontinued abruptly when the patient’s symptoms ameliorate* - Abrupt discontinuation of **lithium** can lead to a **relapse of mood episodes**, including both manic and depressive episodes. - When discontinuing lithium, the dose should be **tapered gradually** under medical supervision to minimize the risk of relapse and withdrawal symptoms.
Explanation: ***TSH and renal function tests*** - The patient was already started on a **mortality-lowering agent** (most likely **lithium**, given its proven anti-suicide efficacy in bipolar disorder) and is now stabilized. - Before continuing mood stabilizer therapy, **baseline TSH and renal function tests are essential** as they are required for safe monitoring of lithium (renal excretion) and to rule out thyroid dysfunction (which can affect mood). - These labs guide **safe long-term management** and should be obtained as soon as the patient is stable enough to cooperate with blood draw. - This represents appropriate **follow-up care** after acute stabilization of a manic episode. *Valproic acid* - While valproic acid is a first-line mood stabilizer for bipolar disorder, the question states a medication was **already started** the previous night. - Starting another mood stabilizer when the patient is already stable and resting peacefully would not be the immediate next step. - If valproic acid were to be considered, it would be as an alternative or adjunct after proper baseline assessment. *Clonazepam* - Clonazepam is a benzodiazepine useful for acute agitation during manic episodes. - Since the patient is now **resting peacefully**, acute sedation is no longer needed. - Benzodiazepines do not address the underlying mood disorder and are not appropriate for long-term management. *CT head* - A CT scan would be indicated if there were signs of organic brain pathology, focal neurological deficits, or first-episode psychosis requiring workup. - This patient has a clear **psychiatric history** (depression) and SSRI-induced mania, making a structural brain lesion unlikely. - The clinical picture strongly suggests **bipolar disorder** rather than a neurological cause. *Restart home SSRI* - Restarting an SSRI in a patient who just experienced **SSRI-induced mania** is **contraindicated**. - SSRIs can precipitate or worsen mania in individuals with underlying bipolar disorder. - Antidepressants in bipolar disorder should only be used cautiously with mood stabilizer coverage, if at all.
Explanation: ***Lithium*** - The patient presents with classic symptoms of a **manic episode** including decreased need for sleep, elevated expansive mood, impulsivity (large loan, spontaneous trip, disrobing), increased talkativeness with pressured speech and flight of ideas, and distractibility. The history also suggests episodes of depression, indicating **bipolar I disorder**. - **Lithium** is a first-line treatment for acute mania and for long-term mood stabilization in bipolar disorder, effective in reducing the severity and frequency of mood episodes. *Observation* - The patient's symptoms are severe, impacting his social and occupational functioning, and involve significant risk-taking behaviors (spending $30,000, taking a large loan). These warrant immediate intervention, not just observation. - Delaying treatment could lead to further financial, legal, or social consequences, as well as an increased risk of self-harm or harm to others due to impaired judgment. *Escitalopram* - **Escitalopram** is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety. - While the patient has a history of depressive episodes, using an antidepressant alone in bipolar disorder can precipitate or worsen a **manic episode**. *Carbamazepine* - **Carbamazepine** is an anticonvulsant that is used as a mood stabilizer in bipolar disorder, particularly for rapid cycling or patients who don't respond to lithium. - While a valid option, **lithium** is generally considered a first-line treatment for acute mania and maintenance therapy for most patients with bipolar disorder due to its established efficacy and safety profile. *Electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is a highly effective treatment for severe mania or depression, especially when there is psychosis, catatonia, or when other treatments have failed, or rapid response is needed. - While effective, it is typically reserved for **treatment-resistant cases** or situations requiring immediate and drastic symptom reduction due to its invasive nature and potential side effects, and is not usually the initial treatment choice.
Explanation: ***Atrialization of the right ventricle in the patient’s fetus*** - This describes **Ebstein's anomaly**, a congenital heart defect linked to **lithium exposure in the first trimester**. - Lithium use during early pregnancy significantly increases the risk of this serious cardiac malformation in the fetus. *Tardive dyskinesia* - This is a movement disorder characterized by involuntary, repetitive body movements, typically associated with **long-term use of dopamine receptor-blocking antipsychotics**. - It is not a known adverse effect of lithium. *Hyperprolactinemia and galactorrhea* - These conditions are commonly associated with antipsychotic medications, particularly **first-generation antipsychotics** and some **second-generation antipsychotics (e.g., risperidone)**, due to their dopamine-blocking effects. - Lithium does not typically cause hyperprolactinemia or galactorrhea. *Stevens-Johnson syndrome* - This is a severe, life-threatening mucocutaneous reaction often triggered by medications, most notably **lamotrigine**, **carbamazepine**, and certain **antibiotics (e.g., sulfonamides)**. - While various drugs can cause it, lithium is not a primary or common cause. *Weight loss* - Lithium commonly causes **weight gain** as a side effect, rather than weight loss. - Weight loss is often associated with other psychotropic medications like bupropion or topiramate, or can be a symptom of conditions like hyperthyroidism, which lithium can paradoxically induce.
Explanation: ***Valproic acid*** - **Valproic acid** is an **anticonvulsant** commonly used as a **mood stabilizer** in bipolar disorder, especially for rapid cycling or mixed manic episodes. - Its broad-spectrum anticonvulsant properties make it effective for various seizure types, in addition to its use in bipolar disorder, fitting the description of a drug used for both. *Lithium* - While **lithium** is a first-line treatment for **bipolar disorder**, it is not primarily an **anticonvulsant** drug, making it less likely given the specific prompt. - It has a narrow therapeutic index and requires regular monitoring, which can be a consideration in treatment compliance. *Phenobarbital* - **Phenobarbital** is an older **barbiturate anticonvulsant** and sedative, but it is not typically used for treating **bipolar disorder** due to its significant side effects and potential for dependence. - Its primary use is in seizure control, not mood stabilization. *Diazepam* - **Diazepam** is a **benzodiazepine** used for acute anxiety, seizures, and muscle spasms, but it is not a primary **mood stabilizer** for bipolar disorder. - It would be used for acute agitation or anxiety symptoms, not long-term mood regulation. *Clonazepam* - **Clonazepam** is another **benzodiazepine** with anticonvulsant properties, often used for anxiety and panic disorders, but generally not as a primary mood stabilizer in **bipolar disorder**. - While it can help with acute agitation, it does not address the underlying mood dysregulation of bipolar disorder.
Explanation: ***Venlafaxine*** - The patient's presentation of depression followed by a rapid shift to **euphoria**, **bizarre behavior**, **rapid speech**, and **psychomotor agitation** after starting an antidepressant strongly suggests **antidepressant-induced mania**. - This response is characteristic of an underlying **bipolar disorder** unmasked by an antidepressant, particularly a **serotonin-norepinephrine reuptake inhibitor (SNRI)** like venlafaxine. *Bupropion* - Bupropion is a **norepinephrine-dopamine reuptake inhibitor (NDRI)**, not an SNRI, and is less commonly associated with inducing mania compared to SNRIs or SSRIs in vulnerable individuals. - While it can be activating, its specific mechanism primarily targets dopamine and norepinephrine, with less direct serotonin reuptake blockade. *Sertraline* - Sertraline is a **selective serotonin reuptake inhibitor (SSRI)**, which primarily blocks serotonin reuptake. - While SSRIs can induce mania in patients with undiagnosed bipolar disorder, the question specifically states the doctor prescribed an antidepressant that blocks the reuptake of **both serotonin and norepinephrine**. *Fluvoxamine* - Fluvoxamine is also a **selective serotonin reuptake inhibitor (SSRI)**, primarily targeting serotonin, not both serotonin and norepinephrine. - As with other SSRIs, it can induce manic episodes in vulnerable individuals, but it does not fit the description of the prescribed drug's mechanism of action. *Lithium* - Lithium is a **mood stabilizer** primarily used for the treatment of bipolar disorder and prevention of manic/depressive episodes, not an antidepressant. - It would be contraindicated as a first-line treatment for what initially presented as unipolar depression and is used to *treat* rather than *induce* mania.
Explanation: ***Involuntarily admit the patient*** - The patient's statement "I just want out of this life" combined with the **suicide attempt** (cutting her forearm after a text expressing suicidal ideation) indicates a high risk of self-harm. Despite her current verbalizations of feeling better, the **impulsivity** and severity of the attempt warrant involuntary admission for safety. - The sudden shift in mood and desire to go home after a serious suicide attempt, stating "these ups and downs are common for me, but I feel better now," suggests potential **lability** and a continued risk that cannot be safely managed with outpatient follow-up alone. *Have the patient sign a suicide contract before discharge* - **Suicide contracts** have not been consistently shown to be effective in preventing suicide and can create a false sense of security. - Given the **actual suicide attempt** and the patient's underlying psychiatric condition, a contract is insufficient to ensure her safety. *Set up a next-day appointment with the patient’s psychiatrist* - While follow-up with her psychiatrist is crucial, relying solely on a **next-day appointment** is inadequate given the acute and severe nature of the suicide attempt. - There is a significant risk of another attempt before the appointment, and the patient needs the **structured environment and constant observation** of an inpatient setting. *Call the patient’s parents* - While involving the patient's support system is generally helpful, this action does not directly address the immediate **safety risk** posed by the recent suicide attempt. - Parental involvement should be considered, but it is not the primary or most appropriate immediate management for a patient at **high risk of self-harm**. *Discontinue lithium and start valproate* - Modifying psychotropic medication is a decision made by a psychiatrist after a thorough evaluation, often over time, and is not the immediate or most appropriate "management" in the **emergency setting** for an acute suicide attempt. - The priority is **safety and stabilization**, not an immediate medication change, especially given that she is already on a mood stabilizer.
Explanation: ***Haloperidol*** - The patient presents with acute agitation, **psychomotor agitation**, flight of ideas, pressured speech, and potentially **psychotic features** (grandiosity, combative behavior) within the context of a likely manic episode. - **Haloperidol**, a first-generation antipsychotic, is highly effective for rapidly controlling severe agitation and psychotic symptoms in such emergency settings due to its potent dopamine D2 antagonism. *Clozapine* - **Clozapine** is an atypical antipsychotic primarily reserved for **treatment-resistant schizophrenia** or bipolar disorder due to its superior efficacy but higher risk of severe side effects like agranulocytosis. - It is not an appropriate first-line agent for acute agitation or initial treatment of a manic episode given its side effect profile and the need for frequent monitoring. *Sertraline* - **Sertraline** is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, anxiety disorders, and other conditions involving serotonin dysregulation. - Administering an antidepressant like sertraline during an acute manic episode can **worsen mania** or induce rapid cycling, making it contraindicated in this acute presentation. *Lithium* - **Lithium** is a mood stabilizer and a cornerstone treatment for bipolar disorder, particularly for chronic management and prevention of manic and depressive episodes. - While effective, lithium has a **slow onset of action** (days to weeks) and is not suitable for rapid control of acute agitation and psychosis in the emergency setting. *Valproate* - **Valproate** (valproic acid) is an anticonvulsant that also functions as a mood stabilizer, commonly used for acute mania and maintenance treatment of bipolar disorder. - Though effective for mania, like lithium, its onset of action is not as rapid as antipsychotics in controlling severe agitation and acute behavioral disturbances in an emergency.
Explanation: ***Long-term lithium therapy*** - This patient presents with classic symptoms of **mania** (decreased need for sleep, grandiosity, compulsive spending, rapid speech) and a history of both manic and depressive episodes, consistent with **bipolar I disorder**. - **Lithium** is a first-line agent for the **long-term maintenance treatment** of **bipolar I disorder**, particularly effective in preventing both manic and depressive episodes. *Clonazepam therapy for one year* - **Clonazepam** is a **benzodiazepine** primarily used for short-term management of acute agitation or severe insomnia, not for long-term mood stabilization in bipolar disorder. - Long-term use of benzodiazepines carries risks of **tolerance** and **dependence**, making it inappropriate for chronic maintenance treatment. *Sertraline therapy for one year* - **Sertraline** is an **antidepressant** (SSRI) that, when used as monotherapy in bipolar disorder, can induce **mania** or **rapid cycling**. - While periods of depression are mentioned, the current presentation is manic, and mood stabilizers are the priority for long-term management. *Long-term risperidone therapy* - **Risperidone** is a **second-generation antipsychotic** effective in treating acute mania and can be used for maintenance in bipolar disorder, often as an adjunct or in patients who cannot tolerate lithium. - However, for long-term monotherapy in bipolar I disorder, **lithium** is generally considered more effective and is the preferred first-line agent, especially given the history of recurrent episodes. *Long-term clozapine therapy* - **Clozapine** is an **atypical antipsychotic** reserved for **treatment-resistant schizophrenia** and **refractory bipolar disorder**, often due to its significant side effect profile, including **agranulocytosis**. - While it can be effective for severe or refractory cases of bipolar disorder, it is not a first-line long-term treatment given its risks and the availability of safer alternatives.
Explanation: ***Valproic acid*** - This patient presents with symptoms highly suggestive of a **manic episode**, including grandiosity (believing he should be CEO), decreased need for sleep (up all night for days), pressured speech (ranting), and impulsivity with poor judgment (disruptive behavior at a board meeting). - **Valproic acid** is a **first-line, guideline-recommended mood stabilizer** for acute mania. It is particularly effective for managing the core symptoms of mania including mood elevation, irritability, and impulsivity. - It has a relatively rapid onset of action and a favorable side effect profile compared to typical antipsychotics, making it an excellent choice for initial management of acute mania in the emergency setting. *Antidepressants* - Administering **antidepressants** during a manic or hypomanic episode can exacerbate symptoms, potentially leading to a rapid cycling pattern or worsening mania. - Antidepressants are primarily used for depressive episodes in bipolar disorder, typically in conjunction with a mood stabilizer, never as monotherapy in a patient presenting with mania. *Haloperidol* - **Haloperidol** is a typical antipsychotic that can be used for acute agitation in mania, but it does not address the underlying mood dysregulation. - While it may help with immediate behavioral control, mood stabilizers like valproic acid or lithium are preferred as primary treatments because they target the core pathophysiology of bipolar disorder. - Haloperidol also has a higher risk of extrapyramidal symptoms and does not prevent future mood episodes. *Psychotherapy* - **Psychotherapy** is a crucial component of long-term management for bipolar disorder but is not effective as a sole treatment for acute mania. - Patients in acute mania are often too agitated, impulsive, and lack sufficient insight to meaningfully engage in therapeutic interventions. - Psychotherapy should be initiated after mood stabilization with pharmacotherapy. *Clozapine* - **Clozapine** is an atypical antipsychotic reserved for treatment-resistant schizophrenia or treatment-resistant bipolar disorder, particularly with prominent psychotic features that have not responded to multiple other medications. - Given its significant side effect profile, including agranulocytosis requiring regular blood monitoring, it is not a first-line or even second-line treatment for an initial presentation of mania. - This patient has no psychiatric history and requires standard first-line treatment, not a medication reserved for refractory cases.
Explanation: ***Impulsivity, insomnia, increased energy, irritability, and auditory hallucinations for 2 weeks*** - This cluster of symptoms indicates a past **manic episode** with **psychotic features**, characteristic of **Bipolar I disorder**. The duration of 2 weeks meets the diagnostic criteria for a manic episode. - The presence of **auditory hallucinations** during a manic episode signifies **psychosis**, which is a key differentiator in Bipolar I as opposed to Bipolar II. *Elevated mood, insomnia, distractibility, and flight of ideas for 5 days* - While these symptoms suggest a **hypomanic episode**, the duration of 5 days is insufficient to meet the criteria for a manic episode (which requires a minimum of 7 days or hospitalization). - A hypomanic episode, without psychotic features, indicates **Bipolar II disorder**, not Bipolar I. *Insomnia, anxiety, nightmares, and flashbacks for 6 months* - This symptom cluster is highly suggestive of **Post-Traumatic Stress Disorder (PTSD)** due to the presence of nightmares and flashbacks over an extended period. - These symptoms are not indicative of a manic or hypomanic episode, and thus do not point to bipolar disorder. *Auditory hallucinations, paranoia, and disorganized speech for 2 weeks* - This constellation of symptoms suggests a **psychotic disorder** such as **schizophrenia** or **schizophreniform disorder**, especially with auditory hallucinations and disorganized speech dominating the clinical picture. - While psychosis can occur in bipolar disorder, the question specifically asks for symptoms *consistent with bipolar I*, and these symptoms alone do not describe the characteristic mood disturbance (mania) of bipolar disorder. *Impulsivity, rapid mood swings, intense anger, self-harming behavior, and splitting for 10 years* - This pattern of symptoms, particularly the chronic impulsivity, rapid mood swings, intense anger, and splitting, is highly suggestive of **Borderline Personality Disorder (BPD)**. - The chronic nature and specific interpersonal and behavioral challenges are hallmarks of BPD, not primarily a manic or hypomanic episode of bipolar disorder.
Explanation: ***Sertraline*** - This patient exhibits classic **bipolar I disorder** with rapid mood cycling from **mania** (naked in public, grandiose delusions, destroying objects) to **severe depression** (suicidal ideation on Day 1) and back to **mania** (grandiose plans on Day 3). - The key clinical clue is the **rapid return to mania by Day 3** after starting medication during the depressive phase. This suggests **antidepressant-induced mania/mood switch**, a well-known complication of using **SSRI antidepressants** (like sertraline) **without adequate mood stabilization** in bipolar disorder. - **Antidepressants can precipitate manic episodes** within days in bipolar patients, which is why they should be avoided or used only with concomitant mood stabilizers. This question tests recognition of this critical psychiatric principle. *Lithium* - Lithium is a first-line **mood stabilizer** for bipolar disorder and would be appropriate for long-term management. However, lithium **prevents manic episodes** rather than causing them. - Lithium takes **1-2 weeks to reach therapeutic levels**, so it would not explain the rapid mood switch to mania by Day 3. If lithium had been started, we would expect **stabilization or improvement**, not a return to mania. *Quetiapine* - Quetiapine is an **atypical antipsychotic** effective for both acute mania and bipolar depression. It can provide rapid mood stabilization. - If quetiapine was started on Day 1, we would expect **mood stabilization or sedation**, not a switch back to mania. Quetiapine does **not precipitate manic episodes**. *Olanzapine* - Olanzapine is another **atypical antipsychotic** used for acute mania and maintenance in bipolar disorder. - Like quetiapine, olanzapine would **stabilize mood** and reduce manic symptoms, not trigger them. It would not explain the return to mania on Day 3. *Lamotrigine* - Lamotrigine is a mood stabilizer particularly effective for **preventing depressive episodes** in bipolar disorder, though less effective for acute mania. - Lamotrigine **does not precipitate manic episodes** and takes weeks to titrate to therapeutic doses due to risk of Stevens-Johnson syndrome. It would not explain the rapid mood switch observed here.
Explanation: ***Lithium*** - This patient's presentation with alternating periods of severe depression and **hypomania**/**mania** (decreased need for sleep, hyperactivity, increased energy leading to suspension) is highly suggestive of **bipolar disorder**. - **Lithium** is a mood stabilizer and is considered a first-line treatment for managing both manic and depressive episodes in bipolar disorder, especially in adolescents. *Ramelteon* - **Ramelteon** is a melatonin receptor agonist primarily used for the treatment of **insomnia**, particularly for sleep onset difficulties. - It is not indicated for the management of bipolar disorder or its associated mood swings. *Amitriptyline* - **Amitriptyline** is a tricyclic antidepressant (TCA) primarily used for **major depressive disorder**, chronic pain, and sometimes insomnia. - Administering an antidepressant alone to a patient with undiagnosed or untreated bipolar disorder can precipitate **mania** or worsen rapid cycling. *Chlorpromazine* - **Chlorpromazine** is a first-generation antipsychotic primarily used for the treatment of **schizophrenia** and severe behavioral problems. - While it can help manage acute manic episodes due to its sedative properties, it is not a primary mood stabilizer for long-term bipolar disorder treatment and is associated with significant side effects. *Phenobarbital* - **Phenobarbital** is a barbiturate with anticonvulsant and sedative-hypnotic properties, primarily used for **epilepsy** and anxiety. - It is not indicated for the treatment of bipolar disorder and does not have mood-stabilizing effects for this condition.
Explanation: ***Genetic predisposition*** - A strong **genetic predisposition** is a primary predisposing factor for bipolar disorder, as evidenced by a significantly higher concordance rate in monozygotic twins compared to dizygotic twins or the general population. - The patient's presentation with **manic symptoms** (decreased need for sleep, euphoria, irritability, frenzied speech, flight of ideas, erratic behavior) following a history of a **major depressive episode** is highly suggestive of **bipolar I disorder**. *Advanced paternal age* - While advanced paternal age has been associated with an increased risk of some neurodevelopmental disorders like **schizophrenia** and **autism spectrum disorder**, its link to bipolar disorder is less robust and not considered the strongest predisposing factor. - The primary risk factor for bipolar disorder involves heritability rather than specific parental age. *Higher socioeconomic class* - There is **no consistent evidence** to suggest that higher socioeconomic class is a predisposing factor for bipolar disorder. - Bipolar disorder affects individuals across all socioeconomic levels. *Maternal obstetric complications* - Maternal obstetric complications, such as **prenatal infections** or **hypoxia**, have been implicated in the development of certain psychiatric disorders, particularly **schizophrenia**. - However, for bipolar disorder, genetic factors play a far more significant and direct role than obstetric complications. *Being married* - **Marital status** does not serve as a predisposing factor for the development of bipolar disorder. - While relationship challenges can be a consequence or stressor for individuals with bipolar disorder, marriage itself is not a cause.
Explanation: ***Switch to lamotrigine for the 1st trimester*** - **Lamotrigine** is considered a **safer alternative** to lithium during the first trimester of pregnancy due to a lower risk of major congenital malformations - The switch should ideally occur **prior to conception** to minimize fetal exposure to lithium during organogenesis - Lamotrigine has a better safety profile in pregnancy compared to other mood stabilizers like valproate *Continue lithium with close monitoring* - While **lithium** carries a risk of **Ebstein's anomaly** (cardiac malformation), the absolute risk is relatively low (0.05-0.1%) - Some current guidelines support continuing lithium in well-controlled patients with close monitoring, but switching to a safer alternative before conception is generally preferred when feasible - This approach would require high-resolution fetal echocardiography and monitoring of lithium levels *She can be maintained on valproate instead* - **Valproate** is **contraindicated in pregnancy** due to high risk of **neural tube defects** (1-2%), cognitive impairment, and other developmental abnormalities - Switching to valproate would significantly increase fetal risk and is inappropriate *Increase folic acid supplementation and continue lithium* - While folic acid supplementation is important for preventing neural tube defects, the primary concern with lithium is **cardiac malformations (Ebstein's anomaly)**, not neural tube defects - Simply increasing folate does not address the teratogenic risk of lithium - A medication change or careful risk-benefit discussion is more appropriate than just supplementation *Discontinue the lithium* - **Abruptly discontinuing lithium** carries a **high risk of relapse** in bipolar disorder (up to 50% within 6 months) - Relapse during pregnancy can be harmful to both mother and fetus - Any medication changes should be **gradual and planned** in collaboration with psychiatry, not abrupt cessation
Explanation: ***Bipolar II disorder*** - The patient exhibits recurrent episodes of **major depression** (sadness, sleep difficulties, increased appetite) interspersed with periods of **hypomania** (energetic, reduced need for sleep, long periods without eating, successful work performance with promotion) - This pattern is characteristic of **Bipolar II disorder**: major depressive episodes plus at least one hypomanic episode - No evidence of **frank mania** (e.g., psychosis, severe impairment requiring hospitalization) is present, which distinguishes this from Bipolar I disorder *Major depressive disorder with seasonal pattern* - While the patient presents with depressive symptoms, the episodes of **hypomania** (increased energy, decreased need for sleep) rule out unipolar depression - The history of episodes at various times (2 years ago, 9 months ago, current) does not fit a **seasonal pattern** - The **hypomanic phases** between depressive episodes are inconsistent with any form of major depressive disorder *Persistent depressive disorder* - This condition involves **chronic depressive symptoms** lasting at least 2 years, but typically less severe than major depressive episodes - The presence of distinct, severe **major depressive episodes** and recurrent **hypomanic periods** contradicts this diagnosis - Persistent depressive disorder does not include hypomania or mood elevation *Major depressive disorder with atypical features* - Atypical features include **increased appetite**, **hypersomnia**, leaden paralysis, interpersonal rejection sensitivity, and mood reactivity - While increased appetite is present during depressive phases, the alternating periods of **hypomania** exclude this from being major depressive disorder - Any form of major depressive disorder is ruled out by the presence of hypomanic episodes *Cyclothymic disorder* - Cyclothymic disorder involves numerous periods of **hypomanic symptoms** and **depressive symptoms** for at least 2 years, but symptoms do not meet full criteria for major depressive or hypomanic episodes - This patient explicitly experiences **major depressive episodes** (persistent sadness, neurovegetative symptoms lasting 4 months), which exceed the threshold for cyclothymia - The severity and duration of depressive episodes make Bipolar II disorder the correct diagnosis
Explanation: ***Bipolar disorder type I*** - The patient's presentation of lasting **elevated mood**, decreased need for sleep, increased energy, pressured speech, flight of ideas, and impulsive behavior (quitting job, spending savings) are hallmark symptoms of a **manic episode**. - A diagnosis of **Bipolar I Disorder** requires the occurrence of at least one manic episode, which is clearly evident here and distinguishes it from other mood disorders, especially given her prior history of major depressive disorder. *Schizoaffective disorder* - This disorder involves a period of illness during which there is an uninterrupted period of major mood episode (depressive or manic) concurrent with symptoms of **schizophrenia**, such as delusions or hallucinations, for at least 2 weeks in the absence of a major mood episode. - The patient's symptoms are primarily mood-driven and do not include the characteristic psychotic features that persist independently of mood disturbances. *Bipolar disorder type II* - Bipolar II Disorder is characterized by at least one major depressive episode and at least one **hypomanic episode**. - The patient's current symptoms, including significant impairment in social/occupational functioning, are indicative of a **manic episode**, not a hypomanic episode, which by definition does not cause marked impairment or require hospitalization. *Delusional disorder* - This disorder is characterized by the presence of **non-bizarre delusions** that last for at least one month, without other prominent psychotic symptoms or significant impairment in functioning. - While the patient's "genius business plan" might seem delusional, her pervasive mood disturbance, flight of ideas, and significant functional impairment are not consistent with the primary features of delusional disorder. *Attention-deficit hyperactivity disorder* - ADHD is characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, often presenting in childhood. - While there is some overlap in symptoms like impulsivity and difficulty sleeping, the episodic nature, the extent of **mood disturbance**, grandiosity, and **pressured speech** are more characteristic of a manic episode than ADHD.
Explanation: ***Continue lithium lifelong*** - This patient presents with clear symptoms of **bipolar I disorder**, characterized by recurrent episodes of **mania** (as evidenced by the current presentation and two similar episodes in the past year). - **Lithium** is a highly effective **mood stabilizer** for bipolar I disorder and is crucial for preventing future manic and depressive episodes. Lifelong maintenance therapy is recommended to reduce recurrence rates. *Continue lithium until a therapeutic serum lithium level is reached, then taper it* - While achieving a **therapeutic serum lithium level** is essential for acute management, tapering it after symptom resolution would increase the risk of **relapse**, as bipolar disorder requires long-term mood stabilization. - Tapering off lithium prematurely contradicts evidence-based guidelines for preventing recurrent mood episodes in bipolar disorder. *Cross-taper lithium to valproic acid for maintenance therapy* - Although **valproic acid** is another effective mood stabilizer for bipolar disorder, there's no indication to switch from lithium if it's effective and tolerated. Both can be used for maintenance. - Unnecessarily changing an effective medication increases the risk of destabilization during the cross-taper and requires re-establishing therapeutic levels of a new medication. *Discontinue lithium, but re-start in the future if the patient has another manic episode* - Discontinuing lithium and waiting for another manic episode is associated with a significantly **higher risk of relapse** and potential worsening of subsequent episodes over time. - The goal of treating bipolar disorder is to **prevent episodes** rather than waiting for them to occur, which is why long-term prophylactic treatment is critical. *Cross-taper lithium to aripiprazole for maintenance therapy* - **Aripiprazole** is an atypical antipsychotic that can be used as a mood stabilizer, particularly for treating acute mania and sometimes for maintenance in bipolar disorder. - However, similar to valproic acid, there is no compelling reason to switch from lithium if it is effective and well-tolerated. Lithium remains a first-line long-term treatment.
Explanation: ***Bipolar II disorder*** - This patient exhibits symptoms consistent with both **hypomania** (increased energy, decreased need for sleep, irritability, distractibility, spending sprees) and past episodes of **major depression** (fatigue, hypersomnia, crying, indecisiveness, worthlessness). The key distinction for Bipolar II is the presence of at least one hypomanic episode and one major depressive episode, without a full manic episode. - The current symptoms of increased energy and decreased need for sleep for 5 days, along with a significant change in behavior (spending paycheck on a "secret project"), indicate a level of impairment consistent with hypomania, rather than a full-blown mania as the thought process is described as linear. *Major depressive disorder* - While the patient has a history of depressive episodes, the current presentation with **elevated mood, increased energy, and decreased need for sleep** is inconsistent with a unipolar depressive episode. - Major depressive disorder does not involve periods of elevated or irritable mood or increased activity. *Bipolar I disorder* - Bipolar I disorder requires the occurrence of at least one **manic episode**. While the patient's current symptoms are suggestive of a mood elevation, they do not meet the criteria for full mania, which typically involves severe impairment, psychotic features, or hospitalization. - The patient's speech is pressured but her thought process is described as **linear**, which is less typical for a full manic episode where **flight of ideas** or **tangential/disorganized thinking** might be present. *Schizoaffective disorder* - Schizoaffective disorder involves a period of uninterrupted illness during which there is a **major mood episode (depressive or manic) concurrent with symptoms of schizophrenia**, such as delusions or hallucinations. - The patient's symptoms are primarily mood-related, and there is no mention of psychotic symptoms independent of the mood disturbance. *Substance abuse* - Although the patient used cocaine once in high school, there is no evidence of recent substance use that would explain the current symptoms. The symptoms are sustained over days and include a history of recurrent mood disturbances. - While the patient received steroid treatment 2 months ago (which can precipitate mood episodes), the timing and clinical presentation are more consistent with a primary mood disorder rather than a substance/medication-induced disorder.
Explanation: ***Obtain TSH, β-hCG, and serum creatinine concentration*** - This patient presents with symptoms highly suggestive of **mania** (bizarre behavior, incoherent talkativeness, grandiosity, increased energy, pressured speech, flight of ideas). Before initiating treatment, it's crucial to rule out other medical conditions that can **mimic mania**, such as **hyperthyroidism** (TSH), **pregnancy** (β-hCG), or **kidney dysfunction** (creatinine), which can impact medication choice and dosage. - TSH levels are essential as **hyperthyroidism** can cause symptoms like agitation, rapid speech, and increased energy, mimicking mania. A **pregnancy test (β-hCG)** is critical for women of childbearing age to ensure that any potential psychiatric medications are safe for both the mother and fetus. **Serum creatinine** helps assess kidney function, which is important for dosing many psychotropic medications eliminated by the kidneys. *Obtain CBC, liver function studies, and beta-HCG* - While a **β-hCG** is appropriate, **CBC** and **liver function studies (LFTs)** are typically obtained if there are specific concerns for anemia, infection, or liver damage (which the patient mentions about valproate in childhood, but there's no immediate indication for current LFTs before diagnosis confirmation). - Although LFTs are important for certain antidepressant or mood stabilizer monitoring (e.g., valproate, carbamazepine), they are not the most immediate initial screen for ruling out medical mimics of mania in this context as **TSH** and **renal function** are more critical. *Obtain BMI, HbA1c, lipid levels, and prolactin levels* - These tests are important for **monitoring long-term metabolic side effects** of certain antipsychotics and mood stabilizers, but they are not the best initial steps for ruling out acute medical causes of manic symptoms. - **BMI, HbA1c, and lipid levels** are typically assessed *after* diagnosis and initiation of treatment to establish a baseline for future metabolic monitoring. **Prolactin levels** might be checked if there is concern for hyperprolactinemia, which is a side effect of some antipsychotics, but not usually a cause of acute mania. *Perform urine drug testing and begin cognitive behavior therapy* - While **urine drug testing** is often performed in acute psychiatric presentations to rule out substance-induced mania, it is not listed as the *best initial step* alone, as other medical conditions also need to be ruled out concurrently. - **Cognitive behavioral therapy (CBT)** is not an appropriate initial treatment for acute mania due to the patient's severe symptoms, lack of insight, and disorganized thought processes. **Pharmacotherapy** is the cornerstone of acute mania management. *Assess for suicidal ideation and obtain echocardiography* - Assessing for **suicidal ideation** is crucial in every psychiatric evaluation, but it is a mental status component rather than a diagnostic lab test. While important for patient safety, it doesn't rule out medical mimics of mania. - **Echocardiography** is not indicated in the initial work-up of acute mania unless there are specific cardiac symptoms or a history that suggests underlying heart disease.
Explanation: ***Valproic acid and quetiapine*** - This patient presents with symptoms of **acute mania**, including **grandiosity**, **decreased need for sleep**, accelerated speech, and flight of ideas, in the context of bipolar disorder. His **elevated serum creatinine (2.5 mg/dL) indicates significant renal impairment**, which necessitates **lithium discontinuation**. - The renal impairment may be due to **lithium-induced nephrotoxicity** (a known complication of chronic lithium therapy), making continuation of lithium both ineffective and potentially dangerous. - **Valproic acid** is an effective mood stabilizer for acute mania and can be safely used in patients with renal impairment (hepatically metabolized), while **quetiapine**, an atypical antipsychotic, targets the psychotic symptoms and helps with **agitation and sleep disturbances**. - This combination provides both mood stabilization and rapid control of acute manic symptoms. *Lithium and olanzapine* - The patient's **serum creatinine of 2.5 mg/dL indicates significant renal impairment**, making lithium, which is renally cleared and can be nephrotoxic, **contraindicated**. - Continuing lithium in the setting of renal dysfunction increases risk of **lithium toxicity** and further renal damage. - While olanzapine is effective for acute mania, continuing lithium would be unsafe given the patient's kidney function. *Carbamazepine only* - **Carbamazepine** is an alternative mood stabilizer for bipolar disorder, but **monotherapy with carbamazepine is insufficient** for managing severe acute mania with psychotic features and significant agitation. - This patient requires both a mood stabilizer and an antipsychotic for rapid stabilization. - Additionally, carbamazepine requires monitoring for **hematologic and hepatic side effects**. *Clozapine only* - **Clozapine** is reserved for **treatment-resistant cases** of bipolar disorder or schizophrenia that have failed multiple other agents. - It requires intensive monitoring for life-threatening side effects including **agranulocytosis** (weekly/biweekly CBC monitoring) and myocarditis. - It is **not appropriate as a first-line agent** for acute manic stabilization in the emergency setting. *Lithium and valproic acid* - **Lithium is contraindicated** in this patient due to his **elevated serum creatinine (2.5 mg/dL)**, which indicates significant renal impairment. - While valproic acid would be appropriate, combining it with lithium would pose serious safety risks given the renal dysfunction.
Explanation: ***Failure of vertebral arch fusion*** - The patient's presentation (rapid speech, grandiosity, decreased need for sleep, hypersexuality, distractibility) is classic for a **manic episode**, consistent with **bipolar I disorder** - First-line treatment for acute mania includes mood stabilizers, most commonly **valproate (valproic acid)** or lithium - **Valproate** is associated with a **1-2% risk of neural tube defects** including spina bifida (failure of vertebral arch fusion) when exposed during the first trimester - This represents the **highest teratogenic risk** among mood stabilizers for neural tube defects - Given she was treated during her admission and is now 3 months pregnant (first trimester exposure), neural tube defects are a significant concern *Atrialized right ventricle* - This condition (**Ebstein anomaly**) is the classic teratogenic effect associated with **lithium** exposure during pregnancy - The risk is approximately 0.05-0.1% (lower than previously thought) - While lithium could have been used for her acute mania, **valproate is more commonly used as first-line therapy** and has a stronger association with the correct answer (neural tube defects) - If lithium was used, this would be the primary fetal concern *Sirenomelia* - This rare congenital malformation (fused lower extremities resembling a mermaid) is associated with **maternal diabetes mellitus** and vascular disruption - Not associated with mood stabilizer exposure *Cleft palate* - While various teratogens can increase cleft palate risk, this is **not a primary concern** with mood stabilizer exposure - More commonly associated with anticonvulsants like phenytoin or maternal smoking *Phocomelia* - This limb malformation (proximal limb absence with hands/feet attached near trunk) is classically associated with **thalidomide** exposure - Not related to mood stabilizer therapy
Explanation: ***Complete blood count, weekly*** - **Clozapine** can cause **agranulocytosis** (a severe drop in white blood cell count), which is a potentially life-threatening side effect. - Due to this risk, initial treatment with clozapine requires **weekly complete blood count (CBC)** monitoring to detect early signs of agranulocytosis. *Thyroid-stimulating hormone, prior to introducing the medication* - While initial thyroid function tests might be considered in the workup for bipolar disorder, routine and specific monitoring of **TSH** is not a primary requirement for **clozapine** initiation. - **Lithium**, not clozapine, is more directly associated with thyroid dysfunction, so monitoring would be more relevant to the patient's previous medication. *Basic metabolic panel, weekly* - A **basic metabolic panel (BMP)** assesses **electrolyte levels**, **kidney function**, and **glucose**, which can be affected by various psychotropic medications. - While important for overall health monitoring, a **weekly BMP** is not specifically mandated for **clozapine** due to the specific and severe risk of agranulocytosis. *Hemoglobin A1c, weekly* - **Clozapine** is associated with a risk of **metabolic side effects**, including **weight gain**, **dyslipidemia**, and **new-onset diabetes**. - While **HbA1c** is used to monitor long-term glycemic control, it's typically checked less frequently (e.g., quarterly or annually) for metabolic monitoring, not weekly, and is not the primary immediate safety concern for clozapine. *Dexamethasone suppression test, monthly* - The **dexamethasone suppression test (DST)** is used to assess **adrenal gland function** and can be relevant in certain psychiatric conditions like **depression with melancholic features** or to rule out **Cushing's syndrome**. - It is **not a routine monitoring test** for patients starting or on **clozapine** therapy.
Explanation: ***Bipolar II disorder*** - The patient meets criteria for **Bipolar II disorder**: at least one **hypomanic episode** (current presentation) and at least one **major depressive episode** (2-year history with recurrent episodes). - Current hypomanic features include: **decreased need for sleep** (feels rested after 5 hours), **increased energy and libido**, **significant weight loss** (4 kg in one month), **irritability**, and grandiose thinking ("derives energy from the universe"). - She has had **recurrent depressive episodes** over 2 years (episodes 1 year ago and 6 months ago), fulfilling the major depressive episode requirement. - While the hypomania emerged after starting **fluoxetine**, antidepressants commonly **unmask underlying bipolar disorder** rather than cause a separate medication-induced condition. The diagnosis remains **Bipolar II disorder** per DSM-5-TR when there is evidence of an underlying mood disorder pattern. *Medication-induced bipolar disorder* - Substance/medication-induced bipolar disorder requires that symptoms occur **exclusively during substance use** without evidence of an independent bipolar disorder. - This patient's **recurrent pattern** of mood episodes (multiple depressive episodes over 2 years) suggests an **underlying bipolar disorder** that was unmasked by antidepressant treatment, not a purely medication-induced condition. - The temporal relationship with fluoxetine is significant but represents **antidepressant-induced switching** in bipolar disorder, not a separate diagnostic entity. *Delusional disorder* - Requires **non-bizarre delusions** persisting for at least one month as the predominant feature, without prominent mood symptoms. - This patient's primary presentation is a **mood episode** (hypomania) with the "universe" comment being part of her elevated/expansive mood rather than a fixed, systematized delusion. - Functioning remains relatively intact (still enjoys her work). *Cyclothymic disorder* - Involves numerous periods of **hypomanic and depressive symptoms** for at least 2 years, but symptoms never meet full criteria for hypomanic or major depressive episodes. - This patient has **full hypomanic and major depressive episodes**, making Bipolar II disorder the more appropriate diagnosis. - The severity of her current symptoms (significant sleep reduction, 4-kg weight loss, marked functional changes) exceeds cyclothymic disorder. *Schizoaffective disorder* - Requires a **major mood episode** concurrent with **criterion A symptoms of schizophrenia** (delusions, hallucinations) for at least 2 weeks, plus psychotic symptoms without mood symptoms for at least 2 weeks. - This patient has **no hallucinations** and no clear psychotic symptoms independent of her mood state. - Her elevated mood fully accounts for her presentation.
Explanation: ***Bipolar disorder, type II*** − This patient's current symptoms of profound **sadness, anhedonia, low energy, and social withdrawal** are indicative of a major depressive episode. − The history of prior periods of **decreased need for sleep, brilliant ideas, and being easily distracted** suggests a hypomanic episode, a hallmark of bipolar disorder type II. *Major depressive disorder* − While the patient is currently experiencing a **major depressive episode**, the history of previous hypomanic symptoms rules out a diagnosis of unipolar major depressive disorder. − **Major depressive disorder** does not include a history of manic or hypomanic episodes. *Dysthymia* − **Dysthymia** (persistent depressive disorder) is characterized by chronic, milder depressive symptoms lasting at least two years. − The current episode is severe and marked by a clear change from a previous elevated mood state, which is inconsistent with dysthymia. *Schizoaffective disorder* − **Schizoaffective disorder** involves episodes of mood disturbance alongside symptoms of schizophrenia (e.g., hallucinations, delusions) that occur at least two weeks without prominent mood symptoms. − This patient's symptoms are primarily mood-related and do not include psychotic features characteristic of schizophrenia. *Bipolar disorder, type I* − **Bipolar disorder type I** is characterized by the occurrence of at least one manic episode, which involves more severe symptoms, significant impairment, and often psychosis. − The patient's previous "brilliant ideas" and decreased need for sleep describe a **hypomanic episode** rather than a full manic episode and are not associated with marked functional impairment or psychotic features.
Explanation: ***Valproate*** - This patient presents with classic features of a **manic episode** (decreased need for sleep, psychomotor agitation, pressured speech, grandiosity, increased goal-directed activity, impaired judgment) occurring after a prior depressive episode, indicating **bipolar I disorder**. - **Mood stabilizers** are first-line treatment for acute mania. While **lithium** is traditionally considered the gold standard, this patient has **chronic kidney disease requiring hemodialysis**, making lithium relatively **contraindicated** due to its renal excretion and narrow therapeutic index. - **Valproate** is an excellent alternative mood stabilizer for acute mania and maintenance therapy in bipolar disorder, and it is **hepatically metabolized**, making it safer in patients with **renal impairment**. - Other options include atypical antipsychotics (e.g., olanzapine, quetiapine, aripiprazole), but valproate is the appropriate mood stabilizer choice given this clinical context. *Triazolam* - **Triazolam** is a short-acting benzodiazepine used for **insomnia**. - While it may provide symptomatic relief for sleep disturbance, it does **not treat the underlying manic episode** and is not indicated as primary therapy for bipolar mania. - Benzodiazepines may be used as adjunctive agents for acute agitation but are not definitive treatment. *Mirtazapine* - **Mirtazapine** is a tetracyclic antidepressant used for **major depressive disorder**. - Antidepressant monotherapy in bipolar disorder can **precipitate or worsen manic episodes** and is contraindicated during an acute manic phase. - If antidepressants are needed for bipolar depression, they should be combined with mood stabilizers. *Fluoxetine* - **Fluoxetine** is a selective serotonin reuptake inhibitor (SSRI) antidepressant. - Like other antidepressants, using fluoxetine as monotherapy in a patient with bipolar disorder can **induce or exacerbate manic episodes**. - It is inappropriate for treating acute mania. *Bupropion* - **Bupropion** is an atypical antidepressant (norepinephrine-dopamine reuptake inhibitor) used for depression and smoking cessation. - It carries a **higher risk of inducing mania** compared to other antidepressants due to its dopaminergic activity. - It is not appropriate for acute mania treatment and could worsen the patient's current symptoms.
Explanation: ***Start valproic acid and discontinue lithium*** - The patient presents with **elevated creatinine (2.2 mg/dL)** and **elevated BUN (39 mg/dL)**, indicating **acute kidney injury or chronic kidney disease**. - She is currently on **lithium** for bipolar disorder, which is known to cause **nephrogenic diabetes insipidus** and **chronic interstitial nephritis** with long-term use. - The combination of **renal impairment**, **lithium therapy**, and concurrent **ACE inhibitor use (captopril)** creates a high risk for **lithium toxicity**, as ACE inhibitors can increase lithium levels by reducing renal clearance. - **Immediate discontinuation of lithium** is essential, and switching to an alternative mood stabilizer like **valproic acid** is appropriate for managing her bipolar disorder. *Continue medications and add nifedipine* - Continuing lithium in the setting of **renal impairment** would risk worsening toxicity and further kidney damage. - While the patient has **hypertension (155/90 mmHg)**, the acute concern is the renal dysfunction and potential lithium toxicity, which must be addressed first. *Continue medications and start furosemide* - **Furosemide** (a loop diuretic) can actually **worsen lithium toxicity** by promoting sodium excretion, leading to increased lithium reabsorption in the proximal tubules. - Continuing lithium with significant renal impairment is contraindicated and could lead to life-threatening toxicity. *Continue medications and start metformin* - Continuing lithium is inappropriate given the **renal impairment** and risk of toxicity. - Additionally, **metformin is contraindicated** in patients with **creatinine ≥1.5 mg/dL in women** due to risk of lactic acidosis; this patient's creatinine is 2.2 mg/dL. *Start lisinopril and discontinue captopril* - Both lisinopril and captopril are **ACE inhibitors**; switching between them does not address the primary issue of **lithium toxicity risk**. - ACE inhibitors can **increase lithium levels** by reducing renal blood flow and lithium clearance, making continuation of any ACE inhibitor problematic without first addressing the lithium issue.
Explanation: ***Valproate*** - This patient presents with symptoms highly suggestive of a **manic episode** (decreased need for sleep, pressured speech, tangential thought, impulsivity, grandiosity, increased goal-directed activity, excessive involvement in pleasurable activities), indicating **bipolar disorder**. - **Valproate** is a mood stabilizer that is effective for acute mania and long-term maintenance in bipolar disorder, especially when **renal impairment** is present (creatinine 1.8 mg/dL) or **lupus nephritis** (proteinuria, WBC casts), as **lithium** is renally cleared and can exacerbate kidney issues. *Dialectical behavioral therapy* - This therapy is primarily used for **borderline personality disorder** to address emotional dysregulation, interpersonal difficulties, and self-harm behaviors. - While helpful for some mood and impulse control issues, it is not a primary monotherapy for the acute management or long-term stabilization of bipolar disorder. *Escitalopram* - **Escitalopram** is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety disorders. - **Antidepressant monotherapy** in bipolar disorder can precipitate or worsen manic episodes, so it is generally avoided or used cautiously with a mood stabilizer. *Clonazepam* - **Clonazepam** is a benzodiazepine used for acute agitation, anxiety, and insomnia. - While it could help with immediate agitation or insomnia, it is **not a long-term treatment** for bipolar disorder due to its lack of mood-stabilizing effects and potential for dependence. *Lithium* - **Lithium** is a highly effective mood stabilizer for bipolar disorder, particularly for preventing manic episodes. - However, it is primarily **renally excreted**, and this patient has evidence of renal impairment (serum creatinine 1.8 mg/dL, proteinuria, WBC casts), which would make lithium use challenging due to increased risk of **toxicity**.
Explanation: ***Mood stabilizers, antipsychotics*** - This patient presents with symptoms highly suggestive of a **manic episode** (grandiosity, decreased need for sleep, erratic behavior, impulsivity, inappropriate sexual advances), likely in the context of **bipolar disorder** given his history of major depression. - The combination of **mood stabilizers** (e.g., lithium, valproate) and **antipsychotics** (e.g., olanzapine, quetiapine, risperidone, aripiprazole) is the **first-line treatment for acute mania** and represents the most appropriate initial approach. - **Mood stabilizers** provide long-term mood regulation and prevent future episodes, while **antipsychotics** offer rapid control of acute symptoms including agitation, psychotic features, and behavioral disturbances. - This combination addresses both immediate symptom control and long-term management of bipolar disorder. *Mood stabilizers, antipsychotics, benzodiazepines, ECT* - While this comprehensive list includes treatments that may be used for acute mania, it is overly broad for an **initial treatment approach**. - **Benzodiazepines** are adjunctive for acute agitation and insomnia but not part of the core initial treatment regimen. - **ECT** is typically reserved for severe, refractory cases, or when rapid response is critically needed (e.g., catatonia, severe suicidality), not as a routine initial approach. *ECT* - **ECT** is highly effective for severe or treatment-refractory mania, especially with psychotic features or when rapid response is essential. - However, it is not the initial treatment approach; pharmacotherapy with mood stabilizers and antipsychotics is tried first. - ECT is typically considered after other treatments have failed or in life-threatening situations. *Benzodiazepines* - While helpful for managing acute **agitation** and **insomnia** associated with mania, benzodiazepines alone do not address the underlying mood dysregulation. - They are used as **adjunctive therapy** for symptom control, not as monotherapy or primary initial treatment for mania. *Antipsychotics* - **Antipsychotics** alone are effective in reducing agitation and psychotic symptoms in acute mania and can be used as monotherapy in some cases. - However, the **combination** of antipsychotics with mood stabilizers is preferred for comprehensive acute management and represents the most appropriate initial approach, as it addresses both immediate symptom control and long-term mood stabilization.
Explanation: ***Bipolar disorder, type I*** - The patient exhibits classic symptoms of a **manic episode**, including **pressured speech**, **decreased need for sleep**, **reckless behavior** (driving naked), and **grandiosity** (recommending metric system, believing he's "painting the town red"). - The presence of **psychotic features** like auditory hallucinations ("can hear that ringing") further supports a diagnosis of bipolar I disorder with psychotic features, as these symptoms occur during the manic episode. *Schizoaffective disorder* - This disorder requires the presence of an **uninterrupted period of illness** during which there is a **major mood episode** (depressive or manic) concurrent with symptoms of **schizophrenia**. - Additionally, for a diagnosis of schizoaffective disorder, there must be **delusions or hallucinations for at least 2 weeks** in the absence of a major mood episode. This patient's symptoms appear to be primarily mood-driven. *Bipolar disorder, type II* - Bipolar II disorder is characterized by at least one **hypomanic episode** and at least one **major depressive episode**. - The patient's symptoms are severe enough to constitute a **manic episode** (e.g., significant impairment, psychotic features), not merely a hypomanic episode. *Major depressive disorder* - Major depressive disorder involves symptoms such as **depressed mood**, **anhedonia**, changes in sleep or appetite, fatigue, and feelings of worthlessness or guilt. - The patient's presentation is dominated by elevated mood, increased energy, and psychotic features, which are inconsistent with a primary diagnosis of major depressive disorder. *Brief psychotic disorder* - This disorder involves a sudden onset of **psychotic symptoms** lasting less than one month, followed by a **full return to premorbid functioning**. - While psychotic symptoms are present, the pervasive mood disturbance (mania) is the primary driver of the presentation, making a primary psychotic disorder less likely.
Explanation: ***Rapid but interruptible speech pattern*** - The patient's presentation of "hijacking conversations" and "sharing his plans" directly demonstrates **pressured speech**, which is a classic and immediately observable symptom of **mania** or **hypomania**. - **Pressured speech** is rapid, difficult to interrupt, and represents a direct behavioral finding that would be evident during the clinical encounter described. - This is the **most directly observable finding** based on the behavior described in the scenario. *History of major depressive episodes* - While patients with **Bipolar Disorder Type I or II** often have a history of depressive episodes, and this patient's baseline "low energy" suggests past depression, the question asks about findings in the **current condition** (manic episode). - A history of depression would support the diagnosis of bipolar disorder but doesn't describe a current symptom. *Patient completing numerous outstanding projects* - While individuals in a **manic state** may have increased energy and initiate many projects, they typically **lack the focus and sustained attention to complete them** (goal-directed activity without completion). - The described behavior of being "out of control" and "hijacking conversations" suggests disorganized, distractible behavior rather than effective productivity. *Decreased need for sleep* - **Decreased need for sleep** is indeed a core DSM-5 criterion for manic episodes and would almost certainly be present in this patient. - However, the question asks what finding you would **find in this patient's current condition** during the emergency department evaluation. Sleep patterns would need to be elicited through history-taking rather than directly observed. - In contrast, **pressured speech** would be immediately apparent during the encounter, making it the **most likely finding to observe** in real-time. *Irresponsibility* - While **poor judgment and irresponsibility** can be features of **manic episodes** (e.g., reckless spending, sexual indiscretions, risky behavior), "irresponsibility" is a vague term that refers more to a pattern of behavior rather than a specific psychiatric symptom. - The scenario already demonstrates poor judgment (showing up "out of control" to a work party), making this redundant rather than an additional finding.
Explanation: ***Correct: Her diagnosis of unipolar depression is incorrect.*** The patient initially presented with symptoms consistent with a **depressive episode**, but the subsequent emergence of **elevated mood, increased talkativeness, flight of ideas, and distractibility after antidepressant use** strongly suggests a shift to a **manic or hypomanic episode**. This antidepressant-induced mood switch is a hallmark feature revealing **bipolar disorder** that was initially misdiagnosed as unipolar depression. This statement most directly addresses **what is true about this patient's condition** - that the fundamental diagnosis is incorrect. Once we establish the correct diagnosis of bipolar disorder, all treatment and management decisions follow from this. *Incorrect: The patient may have psychotic features.* While patients with severe **mania** can develop **psychotic features** (e.g., delusions, hallucinations), the provided symptoms (elevated mood, increased talkativeness, flight of ideas, distractibility) do not describe psychotic symptoms. There is no information suggesting the presence of **delusions or hallucinations**, which are necessary to diagnose psychotic features. The word "may" makes this theoretically possible but not supported by the clinical presentation described. *Incorrect: The patient may have a history of mania.* While patients with bipolar disorder often have previous undiagnosed episodes, this statement is speculative about her **past history** rather than addressing what is most directly evident from the **current presentation**. The vignette focuses on the antidepressant-induced mood switch, which immediately reveals that the current diagnosis of unipolar depression is incorrect. Whether or not she had previous manic episodes is less relevant than recognizing the misdiagnosis now. *Incorrect: Antidepressants are inappropriate.* This statement is clinically **true in principle** - antidepressants as monotherapy are generally inappropriate for bipolar disorder due to the risk of inducing mania or hypomania. However, this option addresses **treatment implications** rather than directly stating what is true about **the patient's condition itself**. The more fundamental and direct truth is that **her diagnosis is wrong** (bipolar, not unipolar depression). Once the correct diagnosis is established, then the inappropriateness of antidepressant monotherapy follows. Additionally, at the time of initial presentation with pure depressive symptoms, the antidepressant prescription was reasonable based on the information available - the inappropriateness only became clear retrospectively after the mood switch occurred. *Incorrect: Her new symptoms need to last at least 7 days.* For a diagnosis of **mania**, symptoms must last at least **one week** (or any duration if hospitalization is required). However, for **hypomania**, symptoms need to last only **4 consecutive days**. The vignette does not specify whether this is mania or hypomania, nor does it clearly state the duration of the current symptoms beyond "now presents." Therefore, we cannot definitively say a 7-day duration is required - it could be hypomania requiring only 4 days. This statement is not necessarily true.
Explanation: ***Sertraline*** * The patient's presentation with **bizarre behavior**, **increased activity**, **pressured speech**, and **agitation** following treatment for depressed mood strongly suggests a **manic or hypomanic episode**. * **Antidepressants**, especially SSRIs like sertraline, can **induce mania** or hypomania in individuals with undiagnosed **bipolar disorder**. * *Lithium* * Lithium is a **mood stabilizer** primarily used to treat and prevent episodes of **mania** and depression in bipolar disorder. * It would be highly unlikely for lithium to precipitate a manic episode; rather, it would be used to **treat the manic symptoms**. * *Alprazolam* * Alprazolam is a **benzodiazepine** used for short-term treatment of anxiety and panic disorders, acting as a **central nervous system depressant**. * It would typically cause **sedation or calmness**, not the agitation and increased energy seen in a manic episode. * *Valproate* * Valproate (valproic acid) is an **anticonvulsant** that is also used as a **mood stabilizer** in bipolar disorder, similar to lithium. * Like lithium, it is prescribed to **treat manic symptoms** and prevent mood swings, making it an unlikely cause for this presentation. * *Haloperidol* * Haloperidol is a **first-generation antipsychotic** used to treat psychosis and acute agitation in various conditions, including mania. * It would cause **sedation and antipsychotic effects**, reducing agitation and bizarre behavior, rather than inducing them.
Explanation: ***Venlafaxine*** - This patient exhibits symptoms of **mania**, including elevated mood, decreased need for sleep, pressured speech, and reckless behavior (climbing a building, spending savings on climbing gear). The recent initiation of an antidepressant, particularly a **serotonin-norepinephrine reuptake inhibitor (SNRI)** like venlafaxine, can precipitate a manic episode in an individual with underlying bipolar disorder. - The history of "unstable emotions for several months" further suggests undiagnosed bipolar disorder, making him susceptible to antidepressant-induced mania. - **SNRIs carry a higher risk of precipitating mania** compared to SSRIs due to their noradrenergic effects. *Quetiapine* - **Quetiapine** is an atypical antipsychotic often used as a mood stabilizer and frequently prescribed for bipolar disorder, rather than causing mania. - It would typically help to stabilize mood and reduce manic symptoms, and is also sedating, making insomnia less likely. *Selegiline* - **Selegiline** is a monoamine oxidase inhibitor (MAOI) often used for Parkinson's disease or major depressive disorder, but less commonly prescribed as a first-line antidepressant due to dietary restrictions and drug interactions. - While MAOIs can activate some patients, they are not typically associated with the rapid onset and severity of mania described, especially as first-line treatment for a new mood complaint. *Fluoxetine* - **Fluoxetine** is an SSRI antidepressant commonly prescribed for major depressive disorder. While SSRIs can precipitate manic episodes in patients with underlying bipolar disorder, they generally carry a **lower risk** compared to SNRIs or tricyclic antidepressants. - The timing and severity of mania in this case (3 days of no sleep, dangerous behavior) is more characteristic of SNRI-induced mania. *Lithium* - **Lithium** is a mood stabilizer and is a primary treatment for bipolar disorder, used to manage both manic and depressive episodes. - It would be expected to *prevent* or *treat* manic symptoms, not cause them.
Explanation: ***Valproate and olanzapine*** - This patient presents with symptoms highly suggestive of **acute mania**, including elevated mood (full of energy), decreased need for sleep, increased goal-directed activity (online shopping), talkativeness, and grandiosity (job is "beneath her"). - An **antipsychotic** (olanzapine) is effective for rapid control of agitation and psychotic features often seen in acute mania, and a **mood stabilizer** (valproate) is crucial for long-term mood regulation. *Valproate* - While **valproate** is a good choice for **mood stabilization** in bipolar disorder, it may not be sufficient on its own for the rapid control of severe manic symptoms and associated agitation. - In acute mania, particularly with prominent behavioral disturbances, an **antipsychotic** is often added to achieve quicker symptom resolution. *Haloperidol* - **Haloperidol** is an antipsychotic that could help with acute agitation and psychotic features, but it has a high risk of **extrapyramidal side effects** and does not provide mood stabilization. - It is typically reserved for severe agitation or psychosis when other agents are less effective or contraindicated, and it's not ideal as a sole initial treatment given the need for mood stabilization. *Electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is a highly effective treatment for severe mania, especially when associated with psychosis, catatonia, or severe agitation/refractoriness to pharmacotherapy, but it is typically reserved for cases that are **refractory to medication** or are life-threatening due to its invasive nature. - It is not considered a first-line initial treatment when pharmacotherapy can be safely and effectively initiated. *Valproate and venlafaxine* - Combining a **mood stabilizer** (valproate) with an **antidepressant** (venlafaxine) is generally avoided in acute mania as antidepressants can **exacerbate manic symptoms** or induce rapid cycling in bipolar disorder. - Antidepressants are typically used with caution, if at all, and only after mood stabilization is achieved, and they are usually discontinued during acute manic episodes.
Explanation: ***Bipolar disorder, type I*** - The patient experienced a clear **manic episode** characterized by **pressured speech**, **decreased need for sleep**, heightened interest in sexual activity, and impulsive financial decisions (donating savings). This manic episode, lasting for a few weeks, is sufficient to diagnose bipolar I disorder. - The presence of recurrent depressive episodes and alternating mood states, along with a distinct manic episode, confirms the diagnosis of **Bipolar I disorder**. *Cyclothymia* - This involves numerous periods of **hypomanic symptoms** and numerous periods of depressive symptoms for at least two years, but the symptoms are not severe enough to meet the full criteria for a hypomanic or major depressive episode. - The described manic episode, especially the "heightened interest in sexual activity" and "considering donating all their savings," is too severe and extensive to be classified as merely hypomanic. *Major depressive disorder* - This disorder is characterized by one or more major depressive episodes without any history of manic or hypomanic episodes. - The patient's history clearly includes a distinct **manic episode**, which rules out a diagnosis of major depressive disorder. *Schizoaffective disorder* - This disorder involves a period of uninterrupted illness during which there is a **major mood episode (depressive or manic)** concurrent with symptoms of **schizophrenia**. - While there are mood fluctuations, there are no reported **psychotic symptoms** (e.g., hallucinations, delusions apart from mood-congruent guilt) presented in the absence of a major mood episode, which is a key diagnostic criterion for schizoaffective disorder. *Dysthymia* - Also known as **persistent depressive disorder**, this involves chronic low-grade depression lasting for at least two years, with symptoms that are less severe than a major depressive episode. - The patient's history includes clear **major depressive episodes** and, critically, a **manic episode**, which is inconsistent with dysthymia.
Explanation: ***Normal behavior*** * The patient's behavior, including **mood swings**, irritability, increased sleep, and occasional boundary-testing (skipping school), is consistent with typical **adolescent development** and the challenges of this developmental stage. * The absence of significant functional impairment, her continued engagement in activities like gymnastics, and the intermittent nature of the symptoms suggest that her behavior falls within the **normal range of adolescent growth and exploration**. *Major depressive disorder* * **Major depressive disorder** would typically involve more persistent and pervasive symptoms of **depressed mood** or **anhedonia** (loss of interest or pleasure) for at least two weeks, along with other symptoms like significant weight changes, insomnia/hypersomnia, psychomotor agitation/retardation, fatigue, feelings of worthlessness/guilt, difficulty concentrating, or recurrent thoughts of death. * While she experiences tiredness and increased sleep, her ability to engage in gymnastics and spend time with friends, along with periods of "normal" behavior, does not align with the diagnostic criteria for **major depressive disorder**, which implies more constant functional impairment. *Premenstrual syndrome* * **Premenstrual syndrome (PMS)** symptoms are directly linked to the **luteal phase** of the menstrual cycle, consistently resolving with menstruation or shortly thereafter. * The patient's mood swings and other behavioral changes are reported over a 6-month period and are not explicitly tied to her 15- to 45-day menstrual cycle, making **PMS** less likely. *Borderline personality disorder* * **Borderline personality disorder** is characterized by a pervasive pattern of **instability of interpersonal relationships**, self-image, affects, and marked impulsivity, often including features like frantic efforts to avoid abandonment, unstable self-image or sense of self, impulsivity in at least two areas that are potentially self-damaging, recurrent suicidal behavior or self-mutilation, affective instability, chronic feelings of emptiness, intense anger, and transient stress-related paranoid ideation or severe dissociative symptoms. * While mood swings are present, the overall clinical picture does not align with the severe and persistent functional impairment and specific diagnostic criteria for **borderline personality disorder**, especially in adolescence where such a diagnosis is made with caution. *Bipolar disorder* * **Bipolar disorder** involves distinct periods of elevated, expansive, or irritable mood (manic or hypomanic episodes) alternating with depressive episodes. * While the patient experiences mood swings and irritability, the description lacks the sustained and severe euphoric, expansive, or irritable mood, increased energy/activity, decreased need for sleep (rather than increased), and other classic symptoms (e.g., grandiosity, flight of ideas, risky behaviors) that define a **manic** or **hypomanic episode**, making **bipolar disorder** an unlikely diagnosis.
Explanation: ***Continue lithium administration through pregnancy*** - Given the available options, this is the **best choice** because the patient has been stable for 2 years on lithium, and **abrupt discontinuation** significantly increases the risk of **relapse** (up to 50-70% risk), which poses serious risks to both mother and fetus. - While lithium carries teratogenic risks including **Ebstein's anomaly** (absolute risk ~0.05-0.1%, relative risk 2-3x baseline), the risk of **untreated bipolar disorder** during pregnancy includes poor prenatal care, substance abuse, risky behaviors, and postpartum psychosis. - **Important clinical context**: In practice, this patient urgently needs **psychiatric consultation** for comprehensive risk-benefit assessment, potential dose adjustment, increased monitoring (lithium levels, fetal echocardiography at 18-20 weeks), and shared decision-making about continuing versus tapering lithium. - For **mild bipolar disorder** with good stability, some guidelines suggest considering a taper in the first trimester, but this must be individualized and closely monitored. *Continue lithium administration through pregnancy and add lamotrigine* - Adding lamotrigine creates unnecessary **polypharmacy** and exposes the fetus to an additional medication when the patient has been stable on lithium monotherapy. - While lamotrigine has a relatively favorable safety profile in pregnancy, there is no clinical indication for augmentation in a stable patient. *Taper lithium and administer valproate* - **Valproate is contraindicated in pregnancy** due to high rates of major congenital malformations (10-20%), including **neural tube defects** (1-5%), cardiac defects, and cognitive/developmental delays (IQ reduction of 7-10 points). - This is never an appropriate option for women of childbearing potential. *Taper lithium and administer carbamazepine* - **Carbamazepine** carries significant teratogenic risk including **neural tube defects** (0.5-1%), craniofacial defects, and developmental delays, making it less safe than continuing lithium. - Switching from a stable medication to one with known substantial risks is not justified. *Taper lithium and provide a prescription for clonazepam as needed* - **Clonazepam** is a benzodiazepine that provides only acute symptomatic relief, not mood stabilization for bipolar disorder. - This would leave the patient **unprotected against mood episodes**, with high risk of manic or depressive relapse during pregnancy. - Discontinuing effective prophylaxis is inappropriate without an adequate replacement strategy.
Explanation: ***Lamotrigine*** - The patient's history of **mania** and current **suicidal ideation** points towards a **bipolar disorder** presentation, for which **lamotrigine** is an excellent mood stabilizer. - Lamotrigine is particularly effective in preventing the **depressive episodes** associated with bipolar disorder, which are often linked to suicidal thoughts and attempts. *Haloperidol* - **Haloperidol** is an **antipsychotic medication** primarily used for acute psychosis, agitation, or severe agitation in bipolar mania. - While agitation might be present, the primary concern is the underlying mood dysregulation and suicidal risk, not acute psychosis. *Escitalopram* - **Escitalopram** is an **SSRI antidepressant**, generally avoided as monotherapy in bipolar disorder as it can precipitate **mania** or **rapid cycling**. - Using an antidepressant alone in a patient with a history of mania can worsen their underlying mood instability. *Diazepam* - **Diazepam** is a **benzodiazepine** used for acute anxiety or sedation. - While it could help with immediate anxiety, it does not address the underlying mood disorder or reduce long-term suicidal risk; its use would be symptomatic and temporary. *Fluoxetine* - **Fluoxetine** is another **SSRI antidepressant** that, like escitalopram, can induce or exacerbate manic episodes in patients with bipolar disorder if not co-administered with a mood stabilizer. - While it treats depression, it is not suitable as a monotherapy for bipolar depression due to the risk of mood destabilization.
Explanation: ***Bipolar I disorder*** - The patient exhibits clear symptoms of a **manic episode**, including decreased need for sleep, grandiosity ("saving the world"), pressured speech, and increased goal-directed activity, which are characteristic of Bipolar I disorder. - The history of a prior hospitalization for similar symptoms ("felt like this on one occasion 2 years ago, and she recalled being hospitalized") and self-reported depressive episodes ("she had no energy... for months") further supports the diagnosis of Bipolar I disorder, which requires at least one manic episode. *Bipolar II disorder* - Bipolar II disorder involves at least one **hypomanic episode** and at least one major depressive episode. - The severity of the patient's current symptoms, including significant functional impairment and a prior hospitalization for similar symptoms, indicates a **manic episode**, not a hypomanic episode. *Major depressive disorder* - This diagnosis is characterized solely by **major depressive episodes** without any history of manic or hypomanic episodes. - The patient's presentation clearly includes symptoms of **mania**, ruling out a sole diagnosis of major depressive disorder. *Persistent Depressive Disorder* - This disorder is characterized by **chronic, mild depressive symptoms** lasting at least two years. - The patient's current presentation of severe manic symptoms and past episodes of clear mania differentiates her condition from persistent depressive disorder. *Schizoaffective disorder* - Schizoaffective disorder involves a period of uninterrupted illness during which there is a **major mood episode (depressive or manic) concurrent with symptoms of schizophrenia**, such as hallucinations or delusions, for at least two weeks in the absence of a major mood episode. - The patient **denies hearing any voices or visual hallucinations**, making schizoaffective disorder less likely; her symptoms are primarily mood-related.
Explanation: ***Lithium*** - The patient exhibits classic symptoms of **mania**, including grandiosity, decreased need for sleep, pressured speech, and flight of ideas, suggesting **bipolar I disorder**. - **Lithium** is considered a first-line agent and the best long-term maintenance therapy for **bipolar I disorder**, effective in reducing both manic and depressive episodes and decreasing suicide risk. *Haloperidol* - **Haloperidol** is a potent typical antipsychotic primarily used for acute management of severe agitation, psychosis, or manic episodes due to its rapid tranquilizing effects. - While it could be used for immediate symptom control, it is not the **best long-term therapy** for mood stabilization in bipolar disorder and carries a high risk of **extrapyramidal side effects**. *Diphenhydramine* - **Diphenhydramine** is an antihistamine with sedative properties, sometimes used for mild insomnia or allergic reactions, but it has no role in the treatment of acute mania or the long-term management of bipolar disorder. - It would not address the underlying mood dysregulation and behavioral symptoms seen in this patient's presentation. *Valproic acid* - **Valproic acid** (divalproex) is an effective mood stabilizer used for bipolar disorder, particularly in patients who cannot tolerate lithium or have rapid cycling. - However, for long-term therapy and overall efficacy, especially considering lithium's proven benefits in reducing suicidality, **lithium** is generally considered the preferred first-line agent, although valproic acid is a strong alternative. *Risperidone* - **Risperidone** is an atypical antipsychotic, primarily used for acute mania or as an adjunct in bipolar depression, and in schizophrenia. - While useful for acute symptom management of psychosis and agitation in bipolar disorder, it is not typically the sole **best long-term maintenance monotherapy** compared to mood stabilizers like lithium, which directly target the mood swings.
Explanation: ***Lithium*** - The patient's symptoms of **polyuria**, **polydipsia**, **confusion**, and **agitation** are consistent with **lithium-induced nephrogenic diabetes insipidus** and potential early neurotoxicity. - **Lithium** is a common mood stabilizer for bipolar disorder but has a narrow therapeutic window. **Nephrogenic diabetes insipidus** occurs in up to 40% of patients on chronic lithium therapy due to impaired renal response to ADH. - The CNS symptoms (confusion, agitation) may indicate lithium levels approaching or in the toxic range, warranting serum level monitoring. *Chlorpromazine* - This is a first-generation antipsychotic often used for psychosis and mania, but it is more commonly associated with **extrapyramidal symptoms**, **sedation**, and **orthostatic hypotension**. - It does not typically cause the triad of polyuria, polydipsia, and confusion suggestive of the patient's presentation. *Carbamazepine* - An anticonvulsant used as a mood stabilizer, it is known for adverse effects such as **drowsiness**, **dizziness**, **ataxia**, and **hyponatremia** (due to SIADH). - While it can cause neurological symptoms, the described polyuria and polydipsia are not typical side effects. *Amitriptyline* - This is a tricyclic antidepressant (TCA) and is not a first-line treatment for bipolar disorder due to the risk of inducing **mania**. - Its side effects include **anticholinergic effects** (dry mouth, constipation, urinary retention), **sedation**, and **cardiac arrhythmias**, which differ from the patient's symptoms. *Valproic acid* - An anticonvulsant and mood stabilizer, it can cause **gastrointestinal upset**, **tremor**, **sedation**, and **hepatic dysfunction**. - While therapeutic monitoring is important, **polyuria** and **polydipsia** are not characteristic side effects, differentiating it from the patient's presentation.
Explanation: ***Haloperidol*** - The patient is presenting with acute **mania** with psychotic features (delusions of being a detective) and behavioral disorganization (trying to break into a museum), requiring rapid tranquilization. - **Haloperidol** is a potent **first-generation antipsychotic** effective for acute agitation and psychotic symptoms in mania, offering rapid symptom control. - **Pregnancy consideration:** The patient's **positive hCG** is significant. Haloperidol is **relatively safe in pregnancy** (FDA Category C) and is appropriate for acute behavioral emergencies when immediate control is needed. *Lithium* - While **lithium** is a first-line mood stabilizer for bipolar disorder, it has a **slow onset of action** (weeks) and is not suitable for acute behavioral emergencies or rapid tranquilization. - **Contraindicated in pregnancy** (especially first trimester) due to risk of **Ebstein's anomaly** and other cardiac malformations (FDA Category D). *Valproic acid* - **Valproic acid** is another effective mood stabilizer for bipolar disorder, but like lithium, it has a **relatively slow onset of action** and is not indicated for acute agitation or psychosis requiring immediate control. - **Highly teratogenic and contraindicated in pregnancy**, with risks including neural tube defects, developmental delays, and reduced IQ (FDA Category D/X). *Fluoxetine* - **Fluoxetine** is an antidepressant and is generally **contraindicated as monotherapy** in bipolar disorder due to the risk of inducing or worsening manic episodes, especially in patients with acute mania. - It could exacerbate the patient's current hyperactive, agitated state. *Electroconvulsive therapy* - **Electroconvulsive therapy (ECT)** is a highly effective treatment for severe mania and is considered **safe in pregnancy** with no teratogenic risk. - While ECT is an excellent option for pregnant patients with severe bipolar disorder, it is typically reserved for cases that are **refractory to pharmacotherapy**, when rapid definitive response is needed due to life-threatening complications, or when severe symptoms persist despite medication. - In this acute behavioral emergency, **pharmacologic rapid tranquilization with haloperidol is the more appropriate immediate next step**, with ECT considered if the patient does not respond to initial management.
Explanation: ***Valproic acid*** - This patient presents with symptoms highly suggestive of **acute mania (Bipolar I disorder)**, including decreased need for sleep, impulsivity (maxing out credit cards), grandiosity (quitting job), pressured speech (excessively talkative), and irritability. **Valproic acid** is a first-line treatment for **acute mania**, particularly when kidney function is impaired. - Given the patient's **chronically impaired renal function**, valproic acid is preferred over lithium as its excretion is primarily hepatic, minimizing the risk of drug accumulation and toxicity in the context of renal impairment. *Lithium* - While **lithium** is a highly effective mood stabilizer for bipolar disorder, it is predominantly cleared renally. - The patient's **impaired renal function** would significantly increase the risk of **lithium toxicity**, making it a less safe and unsuitable choice in this scenario. *Gabapentin* - **Gabapentin** is an anticonvulsant primarily used for neuropathic pain and seizure disorders, sometimes used off-label as an adjunct for anxiety or sleep. - It is **not a primary mood stabilizer** and lacks sufficient evidence for monotherapy treatment of acute mania in bipolar disorder. *Pregabalin* - **Pregabalin**, similar to gabapentin, is an anticonvulsant and neuropathic pain medication. - It is **not indicated as a first-line treatment** for acute mania due to insufficient efficacy as a mood stabilizer. *Lamotrigine* - **Lamotrigine** is an effective mood stabilizer, particularly for the **depressive phases of bipolar disorder**, and for maintenance therapy. - However, it has limited efficacy in treating **acute manic episodes**, making it less suitable for the patient's current presentation.
Explanation: ***Serum thyroid-stimulating hormone*** - **Lithium** can cause **hypothyroidism** due to its inhibitory effects on thyroid hormone synthesis and release, making it crucial to monitor **TSH** levels regularly. - Long-term lithium use has been associated with a higher incidence of **goiter** and frank hypothyroidism, necessitating close endocrine surveillance. *Complete blood count with differential* - While **lithium** can cause **leukocytosis**, monitoring a CBC with differential is generally not a primary endocrine parameter for lithium toxicity. - Neutrophilia is a common but usually benign side effect, not directly indicating endocrine dysfunction. *Serum creatinine* - **Lithium** is primarily excreted by the **kidneys**, and long-term use can lead to **chronic kidney disease** and nephrogenic diabetes insipidus, requiring monitoring of **serum creatinine**. - Although essential for monitoring renal function, serum creatinine is a renal parameter, not an endocrine one. *Serum aminotransferases* - Monitoring **serum aminotransferases** (e.g., ALT, AST) is important for drugs that cause **hepatotoxicity**, but lithium is not primarily associated with significant liver damage. - While liver function can be affected by various medications, it is not a specific or prominent endocrine side effect of lithium. *Serum lithium levels* - Monitoring **serum lithium levels** is critical to ensure therapeutic efficacy and prevent **toxicity**, as it has a narrow therapeutic window. - While vital for patient safety, this is a direct drug level measurement, not an endocrine parameter reflecting hormonal function.
Bipolar I disorder diagnostic criteria
Practice Questions
Bipolar II disorder diagnostic criteria
Practice Questions
Cyclothymic disorder
Practice Questions
Manic episode criteria and features
Practice Questions
Hypomanic episode criteria and features
Practice Questions
Mixed features specification
Practice Questions
Rapid cycling bipolar disorder
Practice Questions
First episode management
Practice Questions
Maintenance therapy principles
Practice Questions
Mood stabilizers mechanisms and selection
Practice Questions
Antipsychotics in bipolar disorder
Practice Questions
Psychosocial interventions
Practice Questions
Bipolar disorder in pregnancy
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free